Volume 7, Issue 1, Pages (April 2014)

Slides:



Advertisements
Similar presentations
4 th Global Summit on Toxicology Philadelphia, PA, USA Aug , 2015.
Advertisements

Volume 134, Issue 7, Pages (June 2008)
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
Volume 152, Issue 5, Pages e6 (April 2017)
Volume 133, Issue 3, Pages (September 2007)
Relationship with Bile acids and Microbiota
Uncoupling Nuclear Receptor LXR and Cholesterol Metabolism in Cancer
Volume 114, Issue 5, Pages (May 1998)
Ulrich Beuers, Michael Trauner, Peter Jansen, Raoul Poupon 
Volume 2, Issue 4, Pages (October 2005)
Bo Angelin, Tobias E. Larsson, Mats Rudling  Cell Metabolism 
The FXR-FGF19 Gut–Liver Axis as a Novel “Hepatostat”
Volume 146, Issue 4, Pages (April 2014)
Julian R. F. Walters, Ali M. Tasleem, Omer S. Omer, W
Volume 14, Issue 5, Pages (February 2016)
Volume 87, Issue 4, Pages (April 2015)
Volume 146, Issue 4, Pages (April 2014)
Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
Volume 15, Issue 1, Pages (January 2012)
Homing in on bile acid physiology
Volume 129, Issue 2, Pages (August 2005)
Gallstone Disease and Cancer Risk: Finding the Bug in the System
Phosphorus: Another Devil in Our Diet?
Volume 102, Issue 6, Pages (September 2000)
Volume 124, Issue 1, Pages (January 2003)
Pascal Ferré, Fabienne Foufelle  Cell Metabolism 
Volume 134, Issue 7, Pages (June 2008)
Volume 152, Issue 5, Pages e6 (April 2017)
Volume 121, Issue 6, Pages (December 2001)
Volume 64, Issue 3, Pages (March 2016)
Targeting the gut-liver axis in liver disease
Frank J. Gonzalez, Changtao Jiang, Andrew D. Patterson 
Volume 141, Issue 4, Pages e5 (October 2011)
Regulation of Bile Acid Synthesis by the Nuclear Receptor Rev-erbα
Volume 126, Issue 3, Pages (March 2004)
Volume 17, Issue 2, Pages (February 2013)
Volume 12, Issue 2, Pages (August 2010)
Volume 24, Issue 1, Pages (July 2016)
Volume 13, Issue 8, Pages (November 2015)
Volume 134, Issue 4, Pages (April 2008)
DCo(H2)ding the Metabolic Functions of SIRT1 in the Intestine
Volume 23, Issue 6, Pages (June 2016)
Emina Halilbasic, Thierry Claudel, Michael Trauner 
Another Shp on the Horizon for Bile Acids
Jinhan He, Shigeru Nishida, Meishu Xu, Makoto Makishima, Wen Xie 
Volume 93, Issue 5, Pages (May 1998)
Chronic Diarrhea Due to Excessive Bile Acid Synthesis and Not Defective Ileal Transport: A New Syndrome of Defective Fibroblast Growth Factor 19 Release 
Volume 17, Issue 6, Pages (June 2013)
Oihane Garcia-Irigoyen, Antonio Moschetta  Cell Metabolism 
Volume 62, Issue 6, Pages (June 2015)
Covering the Cover Gastroenterology
This month in Gastroenterology
Volume 12, Issue 1, Pages (July 2010)
Bo Angelin, Tobias E. Larsson, Mats Rudling  Cell Metabolism 
Volume 21, Issue 2, Pages (February 2015)
Volume 19, Issue 11, Pages (June 2017)
Gerd A. Kullak-ublick, Bruno Stieger, Peter J. Meier  Gastroenterology 
Genetics of Hepatobiliary Diseases
Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor  Sandy T. Hwang, Nancy L. Urizar,
Latest findings in phosphate homeostasis
James L. Boyer, Carol J. Soroka  Gastroenterology 
Volume 140, Issue 3, Pages (March 2011)
Volume 133, Issue 3, Pages (September 2007)
Nuclear receptor regulation of hepatic function
Homing in on bile acid physiology
Figure 1 Bile acid biosynthesis, transport and metabolism
Volume 146, Issue 4, Pages e7 (April 2014)
Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice A–DCholesterol metabolic parameters were.
Volume 125, Issue 2, Pages (August 2003)
Volume 1, Issue 5, Pages (May 2005)
Presentation transcript:

Volume 7, Issue 1, Pages 12-18 (April 2014) Microbiota Modification with Probiotics Induces Hepatic Bile Acid Synthesis via Downregulation of the Fxr-Fgf15 Axis in Mice  Chiara Degirolamo, Stefania Rainaldi, Fabiola Bovenga, Stefania Murzilli, Antonio Moschetta  Cell Reports  Volume 7, Issue 1, Pages 12-18 (April 2014) DOI: 10.1016/j.celrep.2014.02.032 Copyright © 2014 The Authors Terms and Conditions

Cell Reports 2014 7, 12-18DOI: (10.1016/j.celrep.2014.02.032) Copyright © 2014 The Authors Terms and Conditions

Figure 1 Colonization of Gut Microbiota with Probiotic Bacteria Enhances Fecal BA Excretion and BA Deconjugation Phylum- (A) and family- and genus- (B) level modifications of fecal microbiota upon VSL#3 treatment are shown as mean percentage of the total sequences. (C) Mice receiving VSL#3 (filled squares) exhibited increased fecal BA excretion compared to vehicle-treated mice (open circles). Data points represent means ± SEM (n = 6 mice/group for each time point). Although the fecal CA/DCA ratio (D) was unchanged, the conjugated/unconjugated BA ratio (E) decreased in VSL#3 mice (black bars) compared to vehicle (white bars). These metabolic changes were associated with increased fecal BSH expression (F) and enzyme activity (G) in mice receiving probiotic bacteria with L. acidophilus and B. infantis displaying much higher BSH activity compared to S. thermophilus (H). An asterisk indicates significant differences between groups (p < 0.05). Cell Reports 2014 7, 12-18DOI: (10.1016/j.celrep.2014.02.032) Copyright © 2014 The Authors Terms and Conditions

Figure 2 VSL#3 Probiotics Influence Ileal BA Absorption without Modifying Asbt Function (A) ASBT mRNA. (B) Protein levels. (C) Metabolic flux study was performed to assess ileal [3H]-TCA absorption in vehicle and VSL#3-treated mice. (D) Ileal Ostα, Ostβ, and Ibabp expression level. Data are expressed as means ± SEM (n = 6 mice/group). Cyclophillin was used as a housekeeping gene to normalize data and vehicle-treated mice were used as calibrators. An asterisk indicates significant differences between groups (p < 0.05). Cell Reports 2014 7, 12-18DOI: (10.1016/j.celrep.2014.02.032) Copyright © 2014 The Authors Terms and Conditions

Figure 3 VSL#3 Probiotics Modify BA Homeostasis and Induce Hepatic BA Synthesis via Fxr-Fgf15 Axis Downregulation (A–F) Bile acid (A) and TCA/TβMCA ratio (B) in gallbladder bile were increased upon VSL#3 treatment. BA content in liver (C), small intestine lumen (D), pool size (E), and serum (F). (G and H) Hepatic (G) and ileal (H) gene expression profile in vehicle and VSL#3-treated mice. Data are expressed as means ± SEM (n = 6 mice/group). Cyclophillin was used as a housekeeping gene to normalize data, and vehicle-treated mice were used as calibrators. An asterisk indicates significant differences between groups (p < 0.05 and p < 0.01). Bsep, bile salt export pump; Cyp7a1, cholesterol-7alpha-hydroxylase; Cyp8b1, sterol-12alpha-hydroxylase; Fgf15, fibroblast growth factor 15; Fxr, farnesoid X receptor; Lrh1, liver receptor homolog- 1; Ntcp, sodium-dependent taurocholic-cotransporting polypeptide; Shp, small heterodimer partner; TCA, tauro-cholic acid; TβMCA, tauro-β-muricholic acid. Cell Reports 2014 7, 12-18DOI: (10.1016/j.celrep.2014.02.032) Copyright © 2014 The Authors Terms and Conditions

Figure 4 FXR and Fgf15 Deficiency Abolish VSL#3 Probiotic-Mediated Increase of Fecal BA Excretion (A and B) Phylum- (A), family- and genus- (B) level modifications of fecal microbiota of FXR-deficient mice upon VSL#3 treatment are shown as a mean percentage of the total sequences. Data are expressed as means ± SEM (n = 6 mice/group). (C) Fecal BA excretion in wild-type, FXR-, and Fgf15-deficient mice after 21 days of VSL#3 treatment. Cell Reports 2014 7, 12-18DOI: (10.1016/j.celrep.2014.02.032) Copyright © 2014 The Authors Terms and Conditions